Minirin/Ddavp (Desmopressin)

Desmopressin acts on the antidiuretic hormone pathway to manage water balance disorders and certain bleeding conditions.

• Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption.
• Nocturnal enuresis: decreases nighttime bedwetting episodes in children by concentrating urine.
• Hemophilia A (bleeding episodes): enhances clot formation by raising plasma factor VIII levels.
• von Willebrand disease: improves platelet adhesion and reduces bleeding by elevating von Willebrand factor.

• Desmopressin is a synthetic analogue of vasopressin that selectively binds to V2 receptors on the basolateral membrane of renal collecting‑duct cells. Activation of these G‑protein‑coupled receptors stimulates adenylate cyclase, raising intracellular cyclic AMP, which promotes insertion of aquaporin‑2 water channels into the apical membrane. The resulting increase in water permeability enhances free water reabsorption, concentrating urine. In the hemostatic system, desmopressin induces release of stored factor VIII and von Willebrand factor from endothelial cells, augmenting coagulation.

Desmopressin may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Nasal congestion or dryness: especially with intranasal forms, but may occur with tablets.
• Nausea or abdominal discomfort.
• Hyponatremia: mild reduction in serum sodium.
• Flushing or feeling of warmth.

Serious or Rare Side Effects

• Severe hyponatremia with seizures or coma.
• Water intoxication leading to cerebral edema.
• Allergic reactions: rash, itching, or anaphylaxis.
• Thrombotic events: rare clot formation.
• Cardiovascular instability: hypotension or hypertension.

Before prescribing desmopressin, clinicians should consider several safety precautions to minimize risks.

• Assess fluid balance: ensure patients maintain appropriate fluid intake to avoid water overload.
• Monitor serum sodium: especially in the elderly, children, or patients with renal impairment.
• Evaluate renal function: dose adjustment may be needed in severe renal disease.
• Caution in cardiac disease: watch for fluid retention and blood pressure changes.
• Avoid concomitant use with other antidiuretic agents: increases risk of hyponatremia.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Desmopressin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant use with other vasopressin analogues or ADH‑enhancing drugs: may cause profound hyponatremia.
• Strong CYP2C9 inhibitors (e.g., fluconazole): can increase desmopressin plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics (especially thiazides): may exacerbate electrolyte disturbances.
• NSAIDs: can reduce renal prostaglandin synthesis, enhancing antidiuretic effect.
• Antidepressants (SSRIs, SNRIs): increase risk of hyponatremia.
• Anticoagulants: monitor bleeding parameters when used for hemostatic indications.